A Review on 2019-nCoV (SARS-CoV-2) in India

  • Pawan Kumar Mahawar Kota College of Pharmacy, Kota-Rajasthan, India
  • Abhay Sharma Kota College of Pharmacy, Kota, Rajasthan, India


Background: The outbreak of the novel coronavirus, COVID-19, has been declared a pandemic by the WHO on March 11th of 2020. Novel Coronavirus infection mediated pandemic started in China in December 2019 and is still killing 1000s of people throughout the world. The second most populous country, India too is fighting against this infectious disease. The country is taking effective measures to curb the pandemic by exerting extensive campaigning on sanitation and strict social distancing measures to quell the explosion of the infection rate.

 Treatment: No drugs are currently approved for Coronavirus Disease-2019 (COVID-19), although some have been tried. In view of recent studies and discussion on tested drugs on COVID-19 patients of India, I aimed to review existing literature and relevant websites regarding these drugs used in India including allopathic, plasma therapy,Ayurvedic and homeopathic medication.


Keywords: Coronaviridae, Nidovirale, management of stroke, situated patients, allopathic treatment.


Download data is not yet available.

Author Biographies

Pawan Kumar Mahawar, Kota College of Pharmacy, Kota-Rajasthan, India

Kota College of Pharmacy, Kota-Rajasthan, India

Abhay Sharma, Kota College of Pharmacy, Kota, Rajasthan, India

Kota College of Pharmacy, Kota, Rajasthan, India


1. WHO Director-General’s opening remarks at the media briefing on COVID-19. World Health Organisation, 11 March 2020.
2. Richman DD, Whitley RJ, Hayden FG,Clinical virology, 4th ed. Washington: ASM Press; 2016.
3. Yashpal Singh Malik, ShubhankarSircar, SudiptaBhat et al: Emerging Coronavirus Disease (COVID-19), a pandemic public health emergency withanimal linkages, Current status update:12.
4. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organisation, 2020.
5. Ministry of health and family welfare government of India, 2020.
6. PressReleseDetail Press Information Bureau Government of India:1601095.
7. Corona Updates –Ministry of Health and Family Welfare, Government of India, 2020.
8. Munster VJ, Koopmans M, van Doremalen N, van Riel D,de Wit E. Anovel Coronavirus emerging in China‑Keyquestions for impact assessment. N Engl J Med2020; 382:692‑4.
9. Rohit Bhatia, P. N. Sylajaet.al.“Consensus Statement – Suggested Recommendations for Acute Stroke Management during the COVID-19 Pandemic: Expert Group on Behalf of the Indian Stroke Association” official journal of Indian academy of neurology. 2020.
10. Latest update, Ministry of Health and Family Welfare Government of India, 25 May 2020.
11. Tarun Bhatnagar1, Manoj V. Murhekar†, Manish Soneja2 et.al. “Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use” Indian Journal of Medical Research; 2020 March 13:2-3.
12. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends, 2020 Jan 28:01020.
13. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020.
14. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus. Int J Antimicrob Agents, 2020 Feb 17:105923.
15. Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, middle east respiratory syndrome coronavirus (MERSCoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J BiolChem 2016; 291:9218e32.
16. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine
17. as available weapons to fight COVID-19. Int J Antimicrob Agents 2020 Mar 4:105932.
18. Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 2006; 49:2845e9.
19. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a lesstoxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infectionin vitro. Cell Discovery 2020; 6:16.
20. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity andprojection of optimized dosing design of hydroxychloroquine for the treatmentof severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ClinicalInfect Disease, 2020 Mar 9:ciaa237.
21. Mandalam S. Seshadri and T. Jacob John. The COVID-19 Pandemic: Defining the Clinical Syndrome and Describing an Empirical Response. Christian journal for global health; 2020:41
22. Ashok KumarPanda,Amit Kumar Dixit et.al. Ayurveda Practitioners Consensus to Develop Strategies for Prevention and Treatment of Corona Virus Disease (COVID-19). Journal of Ayurveda and integrated medical science, 2020:101-103
23. ImranAli,Omar M.L.Alharbi. COVID-19: Disease, management, treatment, and social impact. science of total environment, 2020:4
289 Views | 317 Downloads
How to Cite
Mahawar, P., & Sharma, A. (2020). A Review on 2019-nCoV (SARS-CoV-2) in India. Asian Journal of Pharmaceutical Research and Development, 8(3), 135-142. https://doi.org/https://doi.org/10.22270/ajprd.v8i3.744